158 related articles for article (PubMed ID: 37019411)
41. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
42. Diffuse intrathyroidal dissemination of papillary thyroid carcinoma with no stromal fibrosis at presentation: A pattern of aggressive differentiated thyroid carcinoma.
Fang H; Si Y; Wang C; Gong Q; Liu C; Wang S
Pathol Res Pract; 2021 Aug; 224():153510. PubMed ID: 34329840
[TBL] [Abstract][Full Text] [Related]
43. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
44. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report.
Shrestha RT; Karunamurthy A; Amin K; Nikiforov YE; Caramori ML
Thyroid; 2015 Dec; 25(12):1375-8. PubMed ID: 26355276
[TBL] [Abstract][Full Text] [Related]
45. Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.
Poma AM; Macerola E; Proietti A; Vignali P; Sparavelli R; Torregrossa L; Matrone A; Basolo A; Elisei R; Santini F; Ugolini C
Front Endocrinol (Lausanne); 2022; 13():842424. PubMed ID: 35311230
[TBL] [Abstract][Full Text] [Related]
46. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
[TBL] [Abstract][Full Text] [Related]
47. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
48. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
49. Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases.
Cameselle-Teijeiro JM; Rodríguez-Pérez I; Celestino R; Eloy C; Piso-Neira M; Abdulkader-Nallib I; Soares P; Sobrinho-Simões M
Am J Surg Pathol; 2017 Jun; 41(6):854-860. PubMed ID: 28009606
[TBL] [Abstract][Full Text] [Related]
50. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
[TBL] [Abstract][Full Text] [Related]
51. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
52. Papillary Thyroid Carcinoma with Desmoid-Like Fibromatosis: Double Trouble?
Juhlin CC; Hysek M; Stenman A; Zedenius J
Endocr Pathol; 2022 Dec; 33(4):525-527. PubMed ID: 36242758
[No Abstract] [Full Text] [Related]
53. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
[No Abstract] [Full Text] [Related]
54. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
[TBL] [Abstract][Full Text] [Related]
55. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up.
Ito Y; Kudo T; Kobayashi K; Miya A; Ichihara K; Miyauchi A
World J Surg; 2012 Jun; 36(6):1274-8. PubMed ID: 22270990
[TBL] [Abstract][Full Text] [Related]
57. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
59. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics.
Timbergen MJM; Starmans MPA; Padmos GA; Grünhagen DJ; van Leenders GJLH; Hanff DF; Verhoef C; Niessen WJ; Sleijfer S; Klein S; Visser JJ
Eur J Radiol; 2020 Oct; 131():109266. PubMed ID: 32971431
[TBL] [Abstract][Full Text] [Related]
60. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]